News

Jun 28, 2021

Shanghai Zhimeng Biopharma appointed Ming Ren as Chief Medical Officer

Jun 09, 2021

Shanghai Zhimeng Biopharma's statement on its scientific advisors

Apr 18, 2021

Zhimeng Biopharma enlisted in Top 100 Biotech Companies in China

Nov 06, 2020

Zhimeng Biopharma Announced Completion of Series A Financing Led by Trinity Innovation Fund (TIF)

Mar 05, 2020

Zhimeng Biopharma Announces the First-in-Human Dosing in Phase I Clinical Trial of ZM-H1505R Designed for the Treatment of Chronic Hepatitis B Virus Infection

Jan 19, 2020

Zhimeng Biopharma Received Approval from US FDA for Starting Clinical Trial on Its HBV Capsid Inhibitor ZM-H1505R

Nov 13, 2019

Zhimeng Biopharma Announced Completion of Series Pre-A Financing Led by Lake Capital and Shenzhen Capital Group Co., Ltd.

Feb 21, 2019

Zhimeng Biopharma announces that it will present new anti-HBV data on its novel hepatitis B virus (HBV) nucleocapsid formation inhibitor CB-001 at the EASL-AASLD Joint Meeting on HBV Endpoints in London, March 8-9, 2019

Nov 09, 2018

Zhimeng Biopharma presented the discovery and efficacy data of its novel hepatitis B virus (HBV) nucleocapsid formation inhibitor CB-001 at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco

Get in touch

Contact Us About Us Leadership Team Scientific Advisors